AstraZeneca Pharma India Limited (ASTRAZEN) Q2 FY27 Financial Results: PAT ₹507 Cr & Revenue ₹6,828 Cr

11 August 2026 · NSE 🔴 High Importance ✨ Positive

By StockFin Research Team•AI-Assisted Analysis•Source: BSE/NSE Filings

Metric	Value
Revenue	₹6,828 Cr
Net Profit (PAT)	₹507 Cr

📢 Key Event

AstraZeneca Pharma India reports 30% YoY revenue growth to INR 6,828 Mn in Q1 FY2026-27

🔮 What's Next

The company expects continued double-digit growth and sustainable long-term value creation through strategic investments in oncology, rare disease, and cardiovascular care initiatives

💡 Investor Takeaway

The company is executing a science-driven growth strategy with strong portfolio momentum and regulatory progress, targeting long-term value creation in key therapeutic areas

AstraZeneca Pharma India reported 30% YoY revenue growth to INR 6,828 Mn in Q1 FY2026-27, driven by oncology, biopharmaceuticals, and rare disease segments, with profit before tax at INR 510 Mn. The company highlighted regulatory approvals for key oncology drugs and strategic initiatives including AI-enabled lung cancer screening in Telangana and K+ Connect for hyperkalaemia management. It emphasized sustained double-digit growth momentum and long-term value creation through science and innovation.

📄 View Original Announcement (PDF)

📊 Stock Analysis — ASTRAZEN ✨ Ask AI About This

About AstraZeneca Pharma India Limited (ASTRAZEN)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹15,635.88 CrP/E: 92.2ROE: 19.4%ROCE: 26.8%Div Yield: 0.58%

View full ASTRAZEN stock details →

📡 Get AI alerts when ASTRAZEN files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track ASTRAZEN — Free

💡 Ask AI about this filing

"What is the revenue contribution split across oncology, biopharmaceuticals, and rare diseases?""When will the Telangana AI lung screening rollout begin and what is the expected adoption timeline?""How does the 3,500% growth in rare diseases compare to prior periods and what is the revenue base?"

Ask AI Free →

📊 More ASTRAZEN filings

🔴 Announcement — 18 September 2026AstraZeneca Pharma India disclosed a penalty of Rs.1.88 lakh imposed by the Registrar of Companies f...
Announcement — 15 September 2026AstraZeneca Pharma India Ltd announced that its trading window will close on September 16, 2026, to ...
🔴 Announcement — 15 September 2026AstraZeneca Pharma India announced the resignation of Dr. Sandeep Arora, Director of Medical Affairs...
🔴 Announcement — 2 September 2026AstraZeneca Pharma India disclosed its ESG rating of 64 from Crisil ESG Ratings, based on FY2026 pub...
Announcement — 25 August 2026AstraZeneca Pharma India Limited disclosed that the Delhi High Court stayed an NPPA demand notice al...

See all ASTRAZEN filings →

🔥 Also filed on 11 August 2026

ULTRACEMCOUltraTech Cement LimitedAnnouncement SUDEEPPHRMSudeep Pharma LimitedFinancial Results SUTLEJTEXSutlej Textiles and Industries LimitedFinancial Results RBZJEWELRBZ Jewellers LimitedFinancial Results TATVATatva Chintan Pharma Chem LimitedCorporate Action AETHERAether Industries LimitedCorporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when ASTRAZEN files new disclosures

Track ASTRAZEN filings, board meetings, and corporate actions. Free email alerts at 5 PM.